KR101851972B1 - Mixed composition to prevent hair loss and promote growing hair providing natural oriental material including artemisiae apiaceae herba, chrysanthemi zawadskii herba, artemisiae argyi herba, artemisiae capillaris herba, sophorae fructus, cirsii herba, and aucklandiae radix extracts and manufacturing method using the same - Google Patents
Mixed composition to prevent hair loss and promote growing hair providing natural oriental material including artemisiae apiaceae herba, chrysanthemi zawadskii herba, artemisiae argyi herba, artemisiae capillaris herba, sophorae fructus, cirsii herba, and aucklandiae radix extracts and manufacturing method using the same Download PDFInfo
- Publication number
- KR101851972B1 KR101851972B1 KR1020150146981A KR20150146981A KR101851972B1 KR 101851972 B1 KR101851972 B1 KR 101851972B1 KR 1020150146981 A KR1020150146981 A KR 1020150146981A KR 20150146981 A KR20150146981 A KR 20150146981A KR 101851972 B1 KR101851972 B1 KR 101851972B1
- Authority
- KR
- South Korea
- Prior art keywords
- herba
- artemisiae
- hair loss
- zawadskii
- chrysanthemi
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 25
- 208000024963 hair loss Diseases 0.000 title claims abstract description 17
- 239000000284 extract Substances 0.000 title claims abstract description 16
- 230000003676 hair loss Effects 0.000 title description 11
- 210000004209 hair Anatomy 0.000 title description 10
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000000463 material Substances 0.000 title description 2
- 241000208173 Apiaceae Species 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000008213 purified water Substances 0.000 claims abstract description 10
- 241000411851 herbal medicine Species 0.000 claims abstract description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 230000003752 improving hair Effects 0.000 claims abstract description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims abstract description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 9
- 230000003658 preventing hair loss Effects 0.000 claims description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 241000209140 Triticum Species 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 239000010779 crude oil Substances 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 241001070947 Fagus Species 0.000 claims 3
- 235000010099 Fagus sylvatica Nutrition 0.000 claims 3
- 239000012141 concentrate Substances 0.000 claims 2
- 239000002131 composite material Substances 0.000 abstract description 15
- 231100000360 alopecia Toxicity 0.000 abstract description 7
- 241000255777 Lepidoptera Species 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 28
- 230000000694 effects Effects 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 18
- 230000001954 sterilising effect Effects 0.000 description 15
- 238000004659 sterilization and disinfection Methods 0.000 description 15
- 208000001840 Dandruff Diseases 0.000 description 13
- 241000555688 Malassezia furfur Species 0.000 description 11
- 210000004761 scalp Anatomy 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 230000000843 anti-fungal effect Effects 0.000 description 7
- 239000002453 shampoo Substances 0.000 description 7
- 239000012895 dilution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001256 tonic effect Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241000208838 Asteraceae Species 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000254032 Acrididae Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- -1 refresher Substances 0.000 description 3
- 239000012898 sample dilution Substances 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 241000282806 Rhinoceros Species 0.000 description 2
- 244000272264 Saussurea lappa Species 0.000 description 2
- 235000006784 Saussurea lappa Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000004916 vomit Anatomy 0.000 description 2
- VPSXHKGJZJCWLV-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylpiperidin-4-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CCN(CC1)CC VPSXHKGJZJCWLV-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- 241001435059 Artemisia argyi Species 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 235000011570 Artemisia caruifolia var apiacea Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 241001331134 Chrysanthemum zawadskii Species 0.000 description 1
- 235000018947 Chrysanthemum zawadskii Nutrition 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 241000729173 Cirsium japonicum Species 0.000 description 1
- 206010065420 Coronary artery dilatation Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- AAFIBPAFMTWDBF-UHFFFAOYSA-N butane-1,3-diol;ethanol Chemical compound CCO.CC(O)CCO AAFIBPAFMTWDBF-UHFFFAOYSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000003645 female-pattern hair loss Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003803 hair density Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- FOKWMWSOTUZOPN-UHFFFAOYSA-N octamagnesium;iron(2+);pentasilicate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Fe+2].[Fe+2].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] FOKWMWSOTUZOPN-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000011025 peridot Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/289—Vladimiria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 포함하는 한약 추출물이 함유된 탈모개선 및 탈모방지용 복합조성물은 정제수에 1,3부틸렌글리콜이 1 ~ 5 % 함유된 혼합수, 청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향의 질량비가 50 : 5 : 5 : 5 : 5 : 1 : 1 : 0.25가 되도록 혼합한 뒤, 추출 및 농축과정을 통해 제조된다.The composite composition for improving hair loss and preventing alopecia contains a herbal medicine extract containing Cheongho, Seulchiae, Lepidoptera, Injinhwa, Beegeum, Daegeum, and Mokcheong, which is a mixed water containing 1 to 5% of 1,3 butylene glycol in purified water, 5: 5: 5: 1: 1: 0.25, followed by extraction and concentration, in order to obtain a mixture having a mass ratio of 50: 5: 5: 5: 5: 1: 1: 0.25.
Description
본 발명은 한약 추출물을 포함하는 탈모개선 및 탈모방지용 복합조성물 및 그 제조방법에 관한 것으로, 더욱 상세하게는 한약추출물을 유효성분으로 포함하는 탈모방지 및 양모 또는 모발의 굵기 증가 치료용 복합 조성물 및 그 제조방법에 관한 것이다.More particularly, the present invention relates to a composite composition for preventing hair loss and for increasing the thickness of wool or hair, which comprises the herbal medicine extract as an active ingredient, and a composition for preventing hair loss, And a manufacturing method thereof.
호르몬에 의한 영향이나, 혈액순환 불량, 영양부족, 약물 부작용, 또는 비듬균이나 세균에 의한 두피손상이나 유전적 요인들에 의해 탈모가 점차 증가하고 있는 추세이다.Hair loss is increasing due to hormonal effects, poor blood circulation, malnutrition, drug side effects, scalp damage due to dandruce or bacteria, or genetic factors.
특히, 최근에는 자극적인 화학 세정제 성분들이나 과도한 스트레스도 두피 및 모발을 손상시킬 수 있는 주요 원인으로 부각되고 있으며, 비듬이나 두피 가려움증도 탈모 증세를 가중시키는 주요한 원인으로 지적되고 있다.In recent years, irritating chemical cleansing agents and excessive stress have become a major cause of damaging the scalp and hair, and dandruff and scalp itching are also pointed out as major causes of hair loss.
탈모증은 남성형 탈모증(male pattern alopecia)과 여성형 탈모증(female pattern hair loss)으로 구분될 수 있고, 그 외에도 원형 탈모증(alopecia areata)이나 기타 원인에 의한 탈모증으로 구분해볼 수 있다.Alopecia can be classified into male pattern alopecia and female pattern hair loss, and alopecia areata or alopecia due to other causes.
상기와 같이 다양하고 복잡한 탈모원인에 대하여 혈액 순환을 촉진하거나 남성 호르몬을 억제하는 성분 등을 이용하여 탈모를 해결하려고 하고 있으나, 아직 뚜렷한 효과를 지닌 방법은 제시되지 않은 것으로 보이고, 일종의 부작용도 유발하는 문제점이 있다.As described above, in order to alleviate hair loss, it is attempted to solve the hair loss by promoting blood circulation or using a component that inhibits male hormone. However, a method having a remarkable effect has not been proposed yet, and a kind of side effect There is a problem.
따라서, 보다 근본적인 탈모 해결책을 제시할 수 있고 다양한 인체 안정성이 확보된 대응방안이 필요한 실정이다.Therefore, there is a need for countermeasures that can provide more fundamental hair loss solution and assure various human stability.
본 발명은 이와 같은 종래의 문제점을 해결하기 위한 것으로, 본 발명의 목적은 보다 효과적인 생체 안정적인 모발 촉진 복합 조성물을 제공하는 것이다.It is an object of the present invention to provide a more effective biostable hair promoting composite composition.
이와 같은 목적을 달성하기 위한 본 발명의 특징에 의하면, 본 발명의 청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 혼합하고 1,3부틸렌글리콜이 질량비로 1 ~ 5 % 함유된 정제수를 추출용매로 하여 추출 및 농축과정을 통해 제조되는 추출물을 함유하는 것이 바람직하다.
본 발명의 혼합수, 상기 청호, 상기 구절초, 상기 애엽, 상기 인진호, 상기 괴각, 상기 대계, 및 상기 목향의 질량비가 100 : 5 ~ 30 : 5 ~ 30 : 5 ~ 30 : 5 ~ 30 : 1~5 : 1~5 : 0.5 ~ 2이 되도록 혼합한 뒤, 추출 및 농축과정을 통해 제조되는 것이 바람직하다.
본 발명의 혼합수, 상기 청호, 상기 구절초, 상기 애엽, 상기 인진호, 상기 괴각, 상기 대계, 및 상기 목향의 질량비가 50 : 5 : 5 : 5 : 5 : 1 : 1 : 0.25인 것이 바람직하다.
본 발명의 혼합수, 상기 청호, 상기 구절초, 상기 애엽, 상기 인진호, 상기 괴각, 상기 대계, 및 상기 목향의 질량비가 50 : 5 : 5 : 5 : 5 : 1 : 1 : 0.25인 것이 바람직하다.According to an aspect of the present invention for achieving the above object, there is provided a process for producing a water-based emulsion, comprising mixing the emulsion of the present invention, the emulsion, the emulsion, the emulsion, As an extraction solvent, and extracting and concentrating the extract.
The mass ratio of the mixed water of the present invention, the crude oil, the petroleum jelly, the lobster, the phosphorus, the cavity, the supernatant and the wheat is 100: 5 to 30: 5 to 30: 5 to 30: 5 to 30: 5: 1 to 5: 0.5 to 2, followed by extraction and concentration.
It is preferable that the mass ratio of the mixed water of the present invention, the blue lake, the rhinoceros, the lobe, the phosphorus lake, the cone angle, the scale, and the wheat are 50: 5: 5: 5: 5: 1: 1: 0.25.
It is preferable that the mass ratio of the mixed water of the present invention, the blue lake, the rhinoceros, the lobe, the phosphorus lake, the cone angle, the scale, and the wheat are 50: 5: 5: 5: 5: 1: 1: 0.25.
삭제delete
삭제delete
삭제delete
삭제delete
삭제delete
본 발명의 농축단계는 상기 혼합물의 추출하여 얻은 추출물의 전체 중량을 70% ~ 80% 정도로 농축하는 것이 바람직하다.In the concentration step of the present invention, the total weight of the extract obtained by extracting the mixture is preferably concentrated to about 70% to 80%.
이와 같은 본 발명에 의한 청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 포함하는 한약 추출물이 함유된 탈모개선 및 탈모방지용 복합조성물 및 그 제조방법에 의하면, 비듬을 방지하고 두피의 가려움증을 억제함으로써 두피 기능을 향상시킴과 동시에 탈모 억제 및 발포 촉진 효과를 가질 수 있으며, 한약재를 이용한 생약성분으로 인해 두피를 자극하지 않고 탈모방지 및 발모촉진을 할 수 있는 이점이 있다.According to the composite composition for preventing and treating alopecia of Alopecia herbaceousum containing the herbal medicine extract, which contains Cheongho, Seulchosha, Lepidoptera, Injinhwa, It is possible to improve the function of the scalp and at the same time to have an effect of inhibiting hair loss and promoting foaming, and there is an advantage that hair loss can be prevented and hair growth can be promoted without stimulating the scalp due to herbal medicine ingredients using herbal medicine materials.
도 1은 청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 포함하는 한약 추출물이 함유된 탈모개선 및 탈모방지용 복합조성물 제조방법을 순차적으로 보인 플로우차트.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flow chart sequentially showing a method for manufacturing a composite composition for improving hair loss and preventing hair loss, which comprises a herbal medicine extract containing Cheongho, Seonjiao, lobule, Injinheo,
본 발명에 관한 설명은 구조적 내지 기능적 설명을 위한 실시예에 불과하므로, 본 발명의 권리범위는 본문에 설명된 실시예에 의하여 제한되는 것으로 해석되어서는 아니 된다. 즉, 실시예는 다양한 변경이 가능하고 여러 가지 형태를 가질 수 있으므로 본 발명의 권리범위는 기술적 사상을 실현할 수 있는 균등물들을 포함하는 것으로 이해되어야 한다. 또한, 본 발명에서 제시된 목적 또는 효과는 특정 실시예가 이를 전부 포함하여야 한다거나 그러한 효과만을 포함하여야 한다는 의미는 아니므로, 본 발명의 권리범위는 이에 의하여 제한되는 것으로 이해되어서는 아니 될 것이다.The description of the present invention is merely an example for structural or functional explanation, and the scope of the present invention should not be construed as being limited by the embodiments described in the text. That is, the embodiments are to be construed as being variously embodied and having various forms, so that the scope of the present invention should be understood to include equivalents capable of realizing technical ideas. Also, the purpose or effect of the present invention should not be construed as limiting the scope of the present invention, since it does not mean that a specific embodiment should include all or only such effect.
한편, 본 출원에서 서술되는 용어의 의미는 다음과 같이 이해되어야 할 것이다.Meanwhile, the meaning of the terms described in the present application should be understood as follows.
"제1", "제2" 등의 용어는 하나의 구성요소를 다른 구성요소로부터 구별하기 위한 것으로, 이들 용어들에 의해 권리범위가 한정되어서는 아니 된다. 예를 들어, 제1 구성요소는 제2 구성요소로 명명될 수 있고, 유사하게 제2 구성요소도 제1 구성요소로 명명될 수 있다.The terms "first "," second ", and the like are intended to distinguish one element from another, and the scope of the right should not be limited by these terms. For example, the first component may be referred to as a second component, and similarly, the second component may also be referred to as a first component.
어떤 구성요소가 다른 구성요소에 "연결되어"있다고 언급된 때에는, 그 다른 구성요소에 직접적으로 연결될 수도 있지만, 중간에 다른 구성요소가 존재할 수도 있다고 이해되어야 할 것이다. 반면에, 어떤 구성요소가 다른 구성요소에 "직접 연결되어"있다고 언급된 때에는 중간에 다른 구성요소가 존재하지 않는 것으로 이해되어야 할 것이다. 한편, 구성요소들 간의 관계를 설명하는 다른 표현들, 즉 "~사이에"와 "바로 ~사이에" 또는 "~에 이웃하는"과 "~에 직접 이웃하는" 등도 마찬가지로 해석되어야 한다.It is to be understood that when an element is referred to as being "connected" to another element, it may be directly connected to the other element, but there may be other elements in between. On the other hand, when an element is referred to as being "directly connected" to another element, it should be understood that there are no other elements in between. On the other hand, other expressions that describe the relationship between components, such as "between" and "between" or "neighboring to" and "directly adjacent to" should be interpreted as well.
단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한 복수의 표현을 포함하는 것으로 이해되어야 하고, "포함하다"또는 "가지다" 등의 용어는 실시된 특징, 숫자, 단계, 동작, 구성요소, 부분품 또는 이들을 조합한 것이 존재함을 지정하려는 것이며, 하나 또는 그 이상의 다른 특징이나 숫자, 단계, 동작, 구성요소, 부분품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.It is to be understood that the singular " include " or "have" are to be construed as including the stated feature, number, step, operation, It is to be understood that the combination is intended to specify that it does not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, or combinations thereof.
각 단계들에 있어 식별부호(예를 들어, a, b, c 등)는 설명의 편의를 위하여 사용되는 것으로 식별부호는 각 단계들의 순서를 설명하는 것이 아니며, 각 단계들은 문맥상 명백하게 특정 순서를 기재하지 않는 이상 명기된 순서와 다르게 일어날 수 있다. 즉, 각 단계들은 명기된 순서와 동일하게 일어날 수도 있고 실질적으로 동시에 수행될 수도 있으며 반대의 순서대로 수행될 수도 있다.In each step, the identification code (e.g., a, b, c, etc.) is used for convenience of explanation, the identification code does not describe the order of each step, Unless otherwise stated, it may occur differently from the stated order. That is, each step may occur in the same order as described, may be performed substantially concurrently, or may be performed in reverse order.
여기서 사용되는 모든 용어들은 다르게 정의되지 않는 한, 본 발명이 속하는 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가진다. 일반적으로 사용되는 사전에 정의되어 있는 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한 이상적이거나 과도하게 형식적인 의미를 지니는 것으로 해석될 수 없다.All terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs, unless otherwise defined. Commonly used predefined terms should be interpreted to be consistent with the meanings in the context of the related art and can not be interpreted as having ideal or overly formal meaning unless explicitly defined in the present application.
본 발명에 의한 한약 추출물을 포함하는 탈모개선 및 탈모방지용 복합조성물은 청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 유효성분으로 포함한다.The composite composition for improving hair loss and preventing alopecia, comprising the herbal extract according to the present invention, contains as an active ingredient the following components: Chungho, Rhus japonica, Liliaceae, Inginiae,
청호는 개똥쑥(Artemisia annua Linne) 또는 개사철쑥(Artemisia apiacea Hance)(국화과 Compositae)의 지상부로서, 항암치료제로 사용되고 비타민C가 풍부하게 함유되어 있으며, 면역력을 증가시키고 피부 진균 억제와 열을 내리고, 혈압 강하작용을 한다.Chung Ho is a topical part of Artemisia annua Linne or Artemisia apiacea Hance (Compositae), which is used as an anticancer drug. It is rich in vitamin C, and it is used to increase immunity, Blood pressure lowering action.
구절초는 원구절초(Chrysanthemum zawadskii)와, 가구절초 (Chrysanthemum indicum)의 종이 포함되며 가을에 피는 대표적인 자생화로 5월 단오에는 줄기가 5 마디가 되고, 9월 9일(음력)이 되면 9 마디가 된다 하여 구절초(九節草)라 불린다. 또한 구절초는 줄기끝에 한 송이 꽃이 피는데 흰 꽃이 신선보다 더 돋보인다 하여 선모초(仙母草)라 불린다. 바닷가를 제외한 전국에 자생하며 특히 높고 깊은 산에서 군락을 형성하여 자란다. 구절초는 종(種)으로는 단일종(單一種)이지만 품종은 몇 가지가 있다. 산구절초는 높이 10~60 ㎝, 꽃 직경 3~6㎝이며, 바위 구절초는 중북부지방의 깊은 산에서 자라는 한국 특산 식물로 높이 20 ㎝, 꽃 직경 2~4㎝이다. 상기 구절초 추출물은 구절초의 다양한 기관 또는 부분, 즉, 잎, 꽃, 열매, 줄기, 뿌리, 가지 및 껍질 등을 추출하여 얻을 수 있고, 바람직하게는 줄기과 잎을 추출하여 얻은 추출물일 수 있다.Chrysanthemum zawadskii and Chrysanthemum indicum species are included in the genus Chrysanthemum. Autumn is a typical native flower of Autumn. In May, the stem becomes 5 words and on September 9 (lunar month) it becomes 9 words. It is called "九 節 草". It is also called 孫 母 草, because one flower blooms at the end of the stem and the white flower stands out more than the fresh one. It grows wild throughout the country except for the beaches, especially in high and deep mountains. It is a single species as a species, but there are several varieties. It is 10 ~ 60 ㎝ in height and 3 ~ 6 ㎝ in flower diameter. The rocky peridot is a Korean specialty plant which grows in the deep mountain of the middle northern part. It is 20 ㎝ in height and 2 ~ 4 ㎝ in flower diameter. The Rhizoma extract can be obtained by extracting various organs or parts of the Rhizoma root, that is, leaves, flowers, fruits, stems, roots, branches and bark, and preferably extracts of stem and leaves.
애엽은 국화과의 황해쑥(Artemisia argyi), 쑥(A. pronceps. var. orientlis) 또는 산쑥(A. montana)의 잎 및 어린줄기를 말린 약재를 말하며, 애구초, 구초, 첨애, 애, 빙대, 의초, 황초, 애호 등으로 불리운다. 애엽은 기혈과 경맥을 따뜻하게 하므로 자궁과 하복부가 허약하고 차서 생기는 자궁 출혈, 임신 중 출혈, 토혈, 코피, 각혈에 지혈 반응을 나타낸다. 또한, 하초가 허약하고 차며 복부에 냉감과 동통이 있는 증상 및 생리불순, 생리통, 대하 등에 사용하며, 습진, 피부가려움증에도 효과가 있다. 약리작용으로 지혈작용, 억균작용, 기관지 평활근 이완작용, 진해거담작용, 수면작용, 자궁흥분유도작용, 과민성 쇼크 보호작용 등이 있는 것으로 알려져있다. 본 발명에서 적용되기에 바람직한 부위는 잎과 줄기이다.The leaf is a plant which dried leaves of Artemisia argyi, A. pronecens var. Orientlis or A. montana and dried young stem of the Asteraceae, It is called the grasshopper, the grasshopper, the grasshopper. The lobe warms the gag blood and the gyeongsam, so the uterus and lower abdomen show weak and bleeding uterine bleeding, pregnancy bleeding, hematemesis, nosebleed, necrotic hemorrhage. Also, it is effective for eczema, skin irritation, eczema, and dermatitis. The pharmacological action is known to have a hemostatic effect, a bacterium action, a bronchial smooth muscle relaxation action, a Jinhae genome action, a sleep action, a uterine excitatory induction action, and an irritable shock protection action. Preferred sites for application in the present invention are leaves and stems.
인진호는 국화과의 사철쑥(Artemisia capillaris)의 지상부를 말린 약재를 말하며, 급성간염으로 발연, 전신황색, 소변이 붉고 적은 증상 등에 사용한다. 또한 만성간염, 간경변증, 간암, 담낭염, 담낭결석에도 사용한다. 습진, 옴, 버짐, 풍진 등의 피부질환과 돌림병으로 열이 몹시 나고 발광하는 증상에도 사용한다. 약리작용으로 담즙 분비 촉진 작용, 간기능 보호작용, 간세포 재생작용, 지질 분해작용, 관상 동맥 확장작용, 혈압 강하작용, 해열, 이뇨 작용, 항미생물 작용, 실험성복수암 세포 억제 효과 등이 보고되었다. 본 발명에 적용되는 부위는 지상부이다.In Jin-Ho is a medicinal herb that dried above the ground of Artemisia capillaris of Asteraceae. It is acute hepatitis and it is used for symptoms such as fuming, whole body yellow, red urine and few symptoms. It is also used for chronic hepatitis, liver cirrhosis, liver cancer, cholecystitis, and gallbladder stones. It is also used for the symptom of burning of the skin due to skin diseases such as eczema, omnis, ringworm, It has been reported that the pharmacological action is to promote bile secretion, hepatic function regeneration, hepatocyte regeneration, lipolysis, coronary artery dilatation, hypotensive action, antipyretic, diuretic, antimicrobial and experimental carcinoma cells. The portion to which the present invention is applied is a ground portion.
괴각은 회화나무 Sophora japonica Linne (콩과 Leguminosae)의 잘 익은 열매로써, 열기를 식히고 화기를 제거하는 효능을 가진다.It is a ripe fruit of Sophora japonica Linne (leguminosae), which has the effect of cooling the heat and removing the fire.
대계는 엉겅퀴 Cirsium japonicum DC. var. ussuriense (Regel) Kitamura 또는 기타 동속근연식물 (국화과 Compositae)의 전초로서, 잎의 생즙은 관절염에 잘 듣는다고 하여 즐겨 먹으며, 또 생즙에 밀가루를 반죽하여 척추가리에스의 환부에 붙여도 효과가 있다 하여 잎을 삶은 물로 줄기나 치질의 세척제로 이용하면 효과가 있다. 엉겅퀴의 뿌리는 잘게 썰어서 볕에 말렸다가 다려 약용하는데 건위, 강장, 소염, 해독, 이뇨제 등으로 쓰이며 신경통에도 효능이 있고, 또 잎을 말렸다가 토혈, 출혈 등의 지혈제로도 효과가 있다.Cirsium Cirsium japonicum DC. there is. Ussuriense (Regel) Kitamura or other outpost (Compositae) is a prelude to the plant, the leaf juice is good to eat because it is well known to arthritis, it is also effective to paste the flour into the juice, Boiled water is effective when used as a cleaning agent for stem and hemorrhoids. Thistle roots are finely chopped and dried in the sun, and they are used medicinally. They are used for dryness, tension, inflammation, detoxification, diuretic, etc. They are also effective for neuralgia. They also work as hemostatic agents such as hematemesis and bleeding after drying the leaves.
목향은 Saussurea lappa Clarke의 학명을 가지는 국화과에 속한 다년생초본인 당목향, 천목향, 월서목향 및 토목향의 뿌리 부분을 의미하는 것으로서, 강한 향기가 있고 휘발성분을 풍부하게 함유하여 기를 잘 통하게 해 소화기의 만성 염증과 장통의 증상에 사용된다. 위통이 심하고 장위의 기운이 체한 것을 치료하는 중요한 약으로서 가슴과 배가 부풀고 아픈 것, 구토, 설사, 아랫배에서 대퇴부쪽으로 당기는 증상 등을 다스린다. 소화불량이나 위확장, 배가 더부룩하고 토하려고 해도 토하지 않을 때 신곡과 함께 쓰면 좋다. 목향에는 항균 작용이 있어서 이질 치료에도 중요하게 사용되는 약재이다.It is a perennial herbaceous perennial plant belonging to Saussurea lappa Clarke which has the scientific name of Saussurea lappa Clarke. It is a root of root, Of chronic inflammation and intestinal symptoms. It is an important medication to cure stomach cramps and intestinal aphasia. It treats chest and abdomen swollen and sore, vomiting, diarrhea, and withdrawing from the belly to the thigh. It is good to write with a new song when it is indigestion and the upper expansion, the ship is big and it does not vomit even if it is vomit. It has antimicrobial action in the eyes and it is a medicinal substance that is important for the treatment of heterogeneity.
<복합조성물의 제조방법>≪ Process for producing composite composition &
본 발명에 의한 복합조성물의 추출방법을 아래와 같이 예시한다.The extraction method of the composite composition according to the present invention is exemplified as follows.
(1) 청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 정제수로 깨끗이 세척한 후, 상온에서 일정시간 건조하여 준비하는 준비 단계와,(1) a preparation step in which the purified water is cleanly washed with purified water, and then dried at room temperature for a predetermined time,
(2) 정제수에 1,3부틸렌글리콜이 질량비로 1 ~ 5 % 함유된 혼합 용매(혼합수) 100kg에 청호 5 ~ 30kg, 구절초 5 ~ 30kg, 애엽 5 ~ 30kg, 인진호 5 ~ 30kg을 넣어서 혼합물을 만들고, 여기에 괴각 1~5kg, 대계 1~5kg, 목향 0.5 ~2kg을 첨가함으로써, 정제수에 1,3부틸렌글리콜이 질량비로 1 ~ 5 %로 혼합된 혼합용매, 청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향의 질량비가 100 : 5 ~ 30 : 5 ~ 30 : 5 ~ 30 : 5 ~ 30 : 1~5 : 1~5 : 0.5 ~ 2가 되도록 혼합하되, 바람직하게는 50 : 5 : 5 : 5 : 5 : 1 : 1 : 0.25이 되도록 혼합하는 혼합 단계와,(2) To 100 kg of mixed solvent (mixed water) containing 1 to 5% by mass of 1,3-butylene glycol in purified water, 5 to 30 kg of Chungho, 5 to 30 kg of Rhizoma root, 5 to 30 kg of lobe, And a mixture solvent of 1 to 5% by mass of 1,3-butylene glycol in purified water and a mixed solvent of a mixture of 1 to 5 kg of beeswax, 1 to 5 kg of beeswax, and 0.5 to 2 kg of wheat bran, The mixture is mixed so that the weight ratio of the main component, the main component, the main component, the main component, the pitch angle, the pitch angle, the grain size and the grain size is from 100: 5 to 30: 5 to 30: 5 to 30: 5 to 30: 1 to 5: 1 to 5: 0.5 to 2, 5: 5: 5: 5: 1: 1: 0.25,
(3) 혼합 단계에 의해 혼합된 혼합물을 일정한 온도 및 시간 동안 추출하여 얻은 추출물 90kg을 다시 70kg이 되도록 농축함으로써 전체중량을 70% 내지 80% 정도 농축하는 농축단계에 의해 추출된다.(3) 90 kg of the extract obtained by extracting the mixed mixture at the predetermined temperature and time by the mixing step is extracted by concentrating the whole weight by 70% to 80% by concentrating it to 70 kg again.
상기와 같이 제조되는 본 발명의 복합조성물에는 상기 성분들외에 부가적인 기능 부여를 위해 당업계에서 통상적으로 사용되는 보조성분이 포함될 수 있다. 예를 들어, 비듬 방지제, 모근 강화제, 모발 보수제, 두피 보호제, 청량제, 보습제, 유연제 등의 보조 성분들이 포함될 수 있으며, 이에 한정되는 것은 아니다. 상기 보조 성분들은 본 발명의 목적을 해치지 않는 범위내에서 당업자에 의해 적절한 비율로 배합될 수 있다.The composite composition of the present invention prepared as described above may contain auxiliary components commonly used in the art for imparting additional functions in addition to the above components. For example, it may include, but is not limited to, an anti-dandruff agent, hair root enhancer, hair restorer, scalp care agent, refresher, moisturizer, The auxiliary components may be formulated in a suitable ratio by those skilled in the art to the extent that the object of the present invention is not impaired.
본 발명의 복합조성물은 당업계에 공지된 다양한 형상으로 제형화될 수 있으며, 예를 들어, 외용액제, 크림제, 연고제, 페이스트, 에어로솔제, 겔제, 왁스제, 마스카라 등의 두피 및 눈썹에 적용시킬 수 있는 국소 도포형과 유연화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 팩, 샴푸, 린스, 앰플 및 트리트먼트 등의 두피 및 피부에 적용할 수 있는 형태로 제형화될 수 있다.The composite composition of the present invention can be formulated into various shapes known in the art and applied to scalp and eyebrows such as external liquids, creams, ointments, pastes, aerosols, gels, waxes and mascaras And can be formulated into a form that can be applied to scalp and skin such as topical application type and softening longevity which can be applied, nutritional lotion, nutritional cream, massage cream, essence, pack, shampoo, rinse, ampoule and treatment.
상기와 같이 제조되는 본 발명에 의한 복합 조성물에 대한 살균실험 및 항진균력 실험결과를 이하에서 설명한다.The results of the sterilization test and the antifungal activity test of the composite composition according to the present invention will be described below.
<< 실험예Experimental Example 1 - 살균력 실험> 1 - Sterility Test>
실험예 1은 본 발명에 의한 복합조성물에 의한 살균 효과를 실험하기 위한 것으로서, Escherichia coli(대장균), Staphylococcus aureus(황색포도상구균), Salmonella typhimurium(살모넬라균), Pseudomonas aeruginosa(녹농균)을 Brain Heart Broth(DIFCO)에 배양 시킨 후, 배양된 세균을 희석하여 초기 세균수가 105 ~106 CFU/mL이 되도록 조정하여 시험에 사용하였다. Experimental Example 1 was conducted to test the bactericidal effect of the composite composition according to the present invention. The experiment was conducted in the same manner as Experimental Example 1 except that Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Pseudomonas aeruginosa were used as Brain Heart Broth (DIFCO), and then cultured bacteria were diluted to adjust the initial number of bacteria to 10 5 -10 6 CFU / mL.
보다 구체적으로 시험용액(복합혼합물) 20mL에 시험균액을 첨가하고 혼합한 후 상온에서 1시간동안 방치하였을 때 세균수를 측정하여 초기 세균수에 대한 살균감소율을 알아보았다. 그리고, 생리식염수를 대조로 하여 세균수를 측정한 것을 초기 세균수로 표시하였다. More specifically, when the test solution was added to 20 mL of the test solution (complex mixture), and the mixture was allowed to stand at room temperature for 1 hour, the number of bacteria was measured to determine the rate of sterilization to the initial number of bacteria. Then, the number of bacteria was measured using a physiological saline as a control, and the number of bacteria was indicated as the initial number of bacteria.
단, 이때 모든 실험의 최초 희석 단계에서는 D/E Neutralizing Broth (DIFCO)를 이용하여 중화시키는 과정을 거쳐 시험을 실시하였으며 배지에서 세균이 증식한 경우, 배지상의 균수에 희석 배스를 곱하여 산출하였으며, 배지에서 세균이 증식하지 않은 경우는 중화단계에서 이루어진 희석배수를 곱하여 산출하였으며, 배지에서 세균이 증식하지 않은 경우는 중화단계에서 이루어진 희석배수를 곱하여 『10미만 (<10)』으로 표시하였다. 생균수 계산은 아래의 [수학식 1]에 따라 측정하였고 살균감소율은 [수학식 2]에 따라 결정하였다.However, in the initial dilution stage of all experiments, neutralization was carried out using D / E Neutralizing Broth (DIFCO). When bacteria were grown in the medium, the number of bacteria on the medium was multiplied by a dilution bath, . The number of bacteria that did not proliferate was multiplied by the dilution factor in the neutralization stage. The number of bacteria that did not proliferate in the medium was multiplied by the dilution factor in the neutralization stage and expressed as "less than 10 (<10)". The viable cell count was calculated according to the following formula (1), and the bactericidal reduction rate was determined according to (2).
[수학식 1][Equation 1]
생균수 계산 : N= C × D(N : 생균수, C : 집락수 (2매의 집락 수 평균치), D : 희석배수 (희석액의 희석배수))(N: number of live cells, C: number of colonies (average number of two colonies), D: number of dilutions (dilution factor of diluted liquid))
[수학식 2]&Quot; (2) "
살균감소율(%) 계산 : R(%) = [(A-B)/A] × 100(R: 살균감소율, A: 초기 세균수, B: 일정시간 후 세균수)(%) = [(A-B) / A] 100 (R: sterilization reduction rate, A: initial number of bacteria, B: number of bacteria after a certain period of time)
상기와 같은 과정에 의한 살균실험 결과는 아래의 표 1에 기재된 바와 같다.The results of the sterilization test by the above procedure are as shown in Table 1 below.
(살균력)After 1 hour treatment
(Sterilization power)
복합혼합물
Complex mixture
토닉
tonic
샴푸
shampoo
트리트먼트
treatment
*( ) : 살균감소율(%) = (A-B)/A × 100* (): Sterilization reduction rate (%) = (A-B) / A × 100
여기에서, A : 초기 세균수Here, A: initial number of bacteria
B : 일정시간 후 세균수 B: Number of bacteria after a certain time
(1) Escherichia coli에 대한 살균시험(1) Sterilization test for Escherichia coli
Escherichia coli에 대한 살균시험 결과, 복합혼합물은 초기 접종균수 [7.5×106 CFU/mL]에서 1시간 처리후 [<10 (10미만) CFU/mL]로 감소하였다. As a result of the sterilization test for Escherichia coli, the complex mixture was reduced to [<10 (less than 10) CFU / mL] after 1 hour treatment with the initial inoculum [7.5 × 106 CFU / mL].
(2) Staphylococcus aureus에 대한 살균시험 (2) Sterilization test for Staphylococcus aureus
Staphylococcus aureus에 대한 살균시험 결과 복합혼합물은 초기 접종균수 [4.9×106 CFU/mL]에서 1시간 처리 후 [<10 (10미만) CFU/mL]로 감소하였다.In the sterilization test for Staphylococcus aureus, the complex mixture was reduced to [<10 (less than 10) CFU / mL] after 1 hour treatment with the initial inoculum [4.9 × 106 CFU / mL].
(3) Salmonella typhimurium에 대한 살균시험(3) Sterilization test for Salmonella typhimurium
Salmonella typhimurium에 대한 살균시험 결과, 복합혼합물은 초기 접종균수 [4.7×106 CFU/mL]에서 1시간 처리후 [<10 (10미만) CFU/mL]로 감소하였다. As a result of the sterilization test for Salmonella typhimurium, the complex mixture was reduced to [<10 (less than 10) CFU / mL] after 1 hour treatment with the initial inoculum [4.7 × 106 CFU / mL].
(4) Pseudomonas aeruginosa에 대한 살균시험(4) Sterilization test for Pseudomonas aeruginosa
Pseudomonas aeruginosa에 대한 살균시험 결과 복합혼합물은 초기 접종균수 [5.8×106 CFU/mL]에서 1시간 처리 후 [<10 (10미만) CFU/mL]로 감소하였다. The sterilization test for Pseudomonas aeruginosa showed that the complex mixture was reduced to [<10 (less than 10) CFU / mL] after 1 hour treatment with the initial inoculum [5.8 × 106 CFU / mL].
<< 실험예Experimental Example 2 - 2 - 항진균력Antifungal activity 실험(Halo test)> Halo test>
실험예 2는 본 발명에 의한 복합조성물에 의한 항진균력 효과를 실험하기 위한 것으로서, pityrosporum ovale(비듬균)균을 Fluid Thioglycollate Medium(DIFCO) 배지에 증균 배양시켜 시험에 사용하였다.Experimental Example 2 was used to test the antifungal effect of the complex composition according to the present invention. The pityrosporum ovale (Diclofenac) was cultured in Fluid Thioglycollate Medium (DIFCO) medium.
준비된 Brewer's Anaerobic Agar (DIFCO) 평판배지 위에 pityrosporum ovale 균액을 멸균된 면봉으로 고르게 접종하고, 멸균된 disc (Φ 8.0)에 시료 원액 20 ㎕를 처리한 뒤 disc를 배지 중앙에 놓은 후, 35±1에서 Anaerobic Jar (DIFCO)를 이용하여 혐기적 조건에서 48시간동안 배양한 후 형성된 저지대 (Inhibition Zone)의 지름을 측정하였다The pityrosporum ovale bacterium was inoculated uniformly onto the prepared Brewer's Anaerobic Agar (DIFCO) plate medium with sterilized cotton swabs, treated with 20 μl of the stock solution in a sterilized disc (Φ 8.0), discs were placed in the center of the medium, Anaerobic Jar (DIFCO) was used to measure the diameter of the inhibition zones formed after incubation for 48 hours under anaerobic conditions
상기와 같은 과정에 의한 결과는 아래의 수학식 3에 의해 판독했다.The result of the above process is read by the following equation (3).
[수학식 3]&Quot; (3) "
성장저지대 : W = Growth Low Zone: W =
(여기에서 , W : 저지대의 폭(mm), T : 시료와 저지대의 전체지름(mm), D : 시료의 지름 (mm))(Where W is the width of the lower zone in mm, T is the total diameter of the sample and the lower zone in mm, and D is the diameter of the sample)
상기와 같은 과정에 의한 항진균실험 결과는 아래의 표 2에 기재된 바와 같다.The result of the antifungal test by the above procedure is as shown in Table 2 below.
※ 성장저지대 : W = ※ Low growth zone: W =
여기에서 , W : 저지대의 폭(mm)W: Width of the low zone (mm)
T : 시료와 저지대의 전체지름(mm)T: Overall diameter of sample and lowland (mm)
D : 시료의 지름 (mm)D: Diameter of sample (mm)
(1) pityrosporum ovale에 대한 항진균실험결과(1) Antifungal test results on pityrosporum ovale
저지대(Inhibition Zone)의 크기를 측정한 결과, 시료 복합혼합물은 pityrosporum ovale에 대하여 저지대를 측정한 결과 4mm, 시료 샴푸는 pityrosporum ovale에 대하여 저지대를 측정한 결과 3mm, 시료 토닉은 pityrosporum ovale에 대하여 저지대를 측정한 결과 3mm, 시료 트리트먼트는 pityrosporum ovale에 대하여 저지대를 측정한 결과 2.5mm의 항진균력을 보였다.As a result of measuring the size of the inhibition zone, the result of measuring the low zone for the pityrosporum ovale and 4mm for the poundrosporum ovale, the sample shampoo was measured 3mm for the pityrosporum ovale, and the sample tonic was low for the pityrosporum ovale As a result of the measurement, 3mm, the sample treatment showed the antifungal activity of 2.5mm against the pityrosporum ovale.
상기 실험예 1 또는 실험예 2에서 사용된 시약 taphylococcus aureus 는 ATTC사에서, Brain Heart Infusion Broth, Brain Heart Infusion Agar, Trypic Soy Agar, D/E Neutralizing Broth, Fluid Thioglycollate Medium, Brewer's Anaerobic Agar, Gaspak EZ Anaerobe Container System (DIFCO, USA)에서 구입하였다.The reagent taphylococcus aureus used in Experimental Example 1 or Experimental Example 2 was purchased from ATTC Co., Ltd., Brain Heart Infusion Broth, Brain Heart Infusion Agar, Trypic Soy Agar, D / E Neutralizing Broth, Fluid Thioglycollate Medium, Brewer's Anaerobic Agar, Gaspak EZ Anaerobe Container System (DIFCO, USA).
<< 실험예Experimental Example 3 - 3 - 모낭세포의Follicular 활성도 실험> Activity experiment>
본 발명에 의한 복합 조성물을 포함하는 복합 혼합물, 토닉, 샴푸, 트리트먼트와 동일한 방법으로 아래의 표 3과 같이 비교예를 제조하였다.Comparative Examples were prepared in the same manner as the complex mixture, tonic, shampoo, and treatment containing the composite composition of the present invention as shown in Table 3 below.
모낭세포의 세포주는 인간 모유두세포를 이용하여 DMEM 배지에 넣어 배양약으로 사용했고, 일정온도 조건 하에서 배양기에서 배양 후 MTT 분석법을 수행했다.The cell lines of the hair follicle cells were cultured in a culture vessel under a constant temperature condition after MTT assay was carried out using human dermal papilla cells in a DMEM culture medium.
MTT 분석법에서는 디쉬에 배양한 인간 모유두세포를 일정기간 동안 배양하여 배양한 세포가 있는 96 웰에 100ul씩 첨가하여 각 실시예 및 비교예에 의한 시료의 최종 농도가 표 4와 같이 형성되도록 하였다.In the MTT assay, human dermal papilla cells cultured on a dish were cultured for a certain period of time, and 100 ul of each of the cells was added to 96 wells so that the final concentrations of the samples according to Examples and Comparative Examples were as shown in Table 4.
그리고, 시료를 처리한 96 웰을 일정기간 동안 다시 배양한 후, MTT 용액을 각 웰에 첨가하여 세포의 생장 정도를 판단하였다. 표 4에는 실시예 1 내지 4와 비교예의 세포 생존율을 나타낸 것으로서, 본 발명에 의한 복합혼합물이 첨가된 실시예에서 모유도의 세포 증식능이 월등히 높다는 것을 확인할 수 있다.Then, the 96 wells treated with the sample were again cultured for a predetermined period, and MTT solution was added to each well to determine the degree of cell growth. Table 4 shows the cell survival rates of Examples 1 to 4 and Comparative Example, and it can be confirmed that the cell proliferation ability of the milk milk is remarkably high in the example in which the complex mixture according to the present invention is added.
<< 실험예Experimental Example 4 - 비듬감소율 간이효력 실험> 4 - Dandruff reduction rate Liver effect test>
탈모와 직접적인 연관이 있는 것으로 알려져 있는 비듬에 대한 효과를 알아보기 위해 비교적 비듬이 많은 환자를 대상으로 간이효력 실험을 실시하였다. 실시예 1 내지 4 및 비교예로 구성된 약제로 세발을 하고 1개월간 누적된 비듬을 채집하여 비듬의 중량을 비교평가하였다.To investigate the effect of dandruff, which is known to be directly related to hair loss, liver efficacy tests were conducted on patients with relatively high dandruff. The dandruff cumulative dandruff accumulated for one month was evaluated by comparing the weight of the dandruff with the medicament composed of Examples 1 to 4 and Comparative Example.
[수학식 4]&Quot; (4) "
비듬감소율(%) = [(시험 전 비듬의 중량(mg) - 시험 개시 1개월 후 비듬의 중량(mg))/시험 전 비듬의 중량(mg)] * 100Density of dandruff (%) = [(Weight of dandruff before test (mg) - Weight of dandruff (mg) 1 month after start of test) / Weight of dandruff before test (mg)] * 100
(두피가려움증 효과 : ++++ : 매우 현저한 개선, +++ : 현저한 개선, ++ : 어느 정도 개선, + : 개선효과 없음)(Scalp itching effect: ++++: very significant improvement, +++: significant improvement, ++: somewhat improved, +: no improvement effect)
<< 실험예Experimental Example 5 - 탈모방지효과 간이효력 실험> 5 - Hair loss prevention effect Liver effect test>
탈모환자에 대한 효과를 알아보기 위해 탈모가 진행되고 있는 환자를 대상으로 3개월 동안 탈모 효과에 대해 간이효력 실험을 실시하였다. 탈모 방지 효과에 대한 판단은 4가지 단계로 평가하여 기록하였다.To investigate the effects of hair loss on patients with alopecia, we performed liver tests on hair loss effects for 3 months. Judgment on the effect of preventing hair loss was evaluated and recorded in four stages.
(탈모방지 효과 : ++++ : 매우 현저한 개선, +++ : 현저한 개선, ++ : 어느 정도 개선, + : 개선효과 없음)(Hair loss prevention effect: ++++: very remarkable improvement, +++: remarkable improvement, ++: somewhat improved, +: no improvement effect)
상기에서는 본 출원의 바람직한 실시예를 참조하여 설명하였지만, 해당 기술 분야의 숙련된 당업자는 하기의 특허 청구의 범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 출원을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다.It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit and scope of the present invention as defined by the following claims It can be understood that
Claims (7)
청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 포함하는 한약 추출물이 함유된 탈모개선 및 탈모방지용 복합조성물.
Which comprises an extract prepared by mixing extract, concentrate with purified water containing 1,3-butylene glycol in a mass ratio of 1 to 5% as an extraction solvent, mixing the extract, concentrate,
A composition for improving hair loss and preventing hair loss, which contains herbal medicine extracts including Cheongho, Seulhwa, Leaf, Injinhwa, Beech,
상기 혼합 정제수, 상기 청호, 상기 구절초, 상기 애엽, 상기 인진호, 상기 괴각, 상기 대계, 및 상기 목향의 질량비가 100 : 5 ~ 30 : 5 ~ 30 : 5 ~ 30 : 5 ~ 30 : 1~5 : 1~5 : 0.5 ~ 2이 되도록 혼합한 뒤, 추출 및 농축과정을 통해 제조되는
청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 포함하는 한약 추출물이 함유된 탈모개선 및 탈모방지용 복합조성물.
The method according to claim 1,
Wherein the mass ratio of the mixed purified water to the crude oil is from 100: 5 to 30: 5 to 30: 5 to 30: 5 to 30: 1: 5: 1 to 5: 0.5 to 2, followed by extraction and concentration
A composition for improving hair loss and preventing hair loss, which contains herbal medicine extracts including Cheongho, Seulhwa, Leaf, Injinhwa, Beech,
상기 혼합 정제수, 상기 청호, 상기 구절초, 상기 애엽, 상기 인진호, 상기 괴각, 상기 대계, 및 상기 목향의 질량비가 50 : 5 : 5 : 5 : 5 : 1 : 1 : 0.25인
청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 포함하는 한약 추출물이 함유된 탈모개선 및 탈모방지용 복합조성물.
3. The method of claim 2,
Wherein the mass ratio of the mixed purified water, the purified water, the rhizome, the lobe, the phosphorus, the cavitation, the supernatant, and the wheat is 50: 5: 5: 5: 5: 1: 1: 0.25
A composition for improving hair loss and preventing hair loss, which contains herbal medicine extracts including Cheongho, Seulhwa, Leaf, Injinhwa, Beech,
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150146981A KR101851972B1 (en) | 2015-10-21 | 2015-10-21 | Mixed composition to prevent hair loss and promote growing hair providing natural oriental material including artemisiae apiaceae herba, chrysanthemi zawadskii herba, artemisiae argyi herba, artemisiae capillaris herba, sophorae fructus, cirsii herba, and aucklandiae radix extracts and manufacturing method using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150146981A KR101851972B1 (en) | 2015-10-21 | 2015-10-21 | Mixed composition to prevent hair loss and promote growing hair providing natural oriental material including artemisiae apiaceae herba, chrysanthemi zawadskii herba, artemisiae argyi herba, artemisiae capillaris herba, sophorae fructus, cirsii herba, and aucklandiae radix extracts and manufacturing method using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170046528A KR20170046528A (en) | 2017-05-02 |
KR101851972B1 true KR101851972B1 (en) | 2018-06-11 |
Family
ID=58742679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150146981A KR101851972B1 (en) | 2015-10-21 | 2015-10-21 | Mixed composition to prevent hair loss and promote growing hair providing natural oriental material including artemisiae apiaceae herba, chrysanthemi zawadskii herba, artemisiae argyi herba, artemisiae capillaris herba, sophorae fructus, cirsii herba, and aucklandiae radix extracts and manufacturing method using the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101851972B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220129896A (en) | 2021-03-17 | 2022-09-26 | 이상록 | Antibacterial and antiviral composition comprising natural extract as an active ingredient and method for preparing the same |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107412054B (en) * | 2017-07-25 | 2021-01-08 | 青春之艾(上海)健康科技有限公司 | Hair-growing shampoo and preparation method thereof |
KR102718109B1 (en) | 2021-10-01 | 2024-10-17 | (주)케어젠 | Peptide having hair loss preventing activity or hair growth promoting activity and use thereof |
KR102691926B1 (en) | 2021-10-01 | 2024-08-06 | (주)케어젠 | Peptide having hair loss preventing activity or hair growth promoting activity and use thereof |
KR102691927B1 (en) | 2021-10-01 | 2024-08-06 | (주)케어젠 | Peptide having hair loss preventing activity or hair growth promoting activity and use thereof |
KR102718110B1 (en) | 2021-10-01 | 2024-10-17 | (주)케어젠 | Peptide having hair loss preventing activity or hair growth promoting activity and use thereof |
KR102695762B1 (en) | 2021-10-01 | 2024-08-19 | (주)케어젠 | Peptide having hair loss preventing activity or hair growth promoting activity and use thereof |
KR102695761B1 (en) | 2021-10-01 | 2024-08-19 | (주)케어젠 | Peptide having hair loss preventing activity or hair growth promoting activity and use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10218737A (en) * | 1997-02-10 | 1998-08-18 | Taisho Pharmaceut Co Ltd | Hair restorer |
SK286666B6 (en) | 1999-04-23 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 5-Pyridyl-1,3-azole compounds, method for the production and use |
KR100747651B1 (en) * | 2006-02-01 | 2007-08-08 | 조점화 | Maintaining hair health and promoting hair growth |
KR101483440B1 (en) * | 2008-05-02 | 2015-01-19 | (주)아모레퍼시픽 | Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same |
KR20100071840A (en) * | 2008-12-19 | 2010-06-29 | 애경산업(주) | A nanoemulsion composition for promoting hair growth and restoration and preparing method thereof |
KR20140100922A (en) | 2014-07-23 | 2014-08-18 | 이찬란 | Detergent composition for pet and the manufacturing method of the same |
-
2015
- 2015-10-21 KR KR1020150146981A patent/KR101851972B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220129896A (en) | 2021-03-17 | 2022-09-26 | 이상록 | Antibacterial and antiviral composition comprising natural extract as an active ingredient and method for preparing the same |
Also Published As
Publication number | Publication date |
---|---|
KR20170046528A (en) | 2017-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101851972B1 (en) | Mixed composition to prevent hair loss and promote growing hair providing natural oriental material including artemisiae apiaceae herba, chrysanthemi zawadskii herba, artemisiae argyi herba, artemisiae capillaris herba, sophorae fructus, cirsii herba, and aucklandiae radix extracts and manufacturing method using the same | |
KR100893106B1 (en) | Composition for hair growth | |
KR20220052311A (en) | Korean traditional herbs shampoo composition and manufacturing method thereof | |
KR100960054B1 (en) | Hair cosmetic composition for improving stste of scalp and preventing fall-out of hair | |
KR101744103B1 (en) | Composition for preventing hair loss and promoting hair growth and mathod for preparing the same | |
KR20160087112A (en) | Flower tea and method for manufacturing therof | |
KR20200139970A (en) | Shampoo for preventing loss of hair andpromoting growth of hair and method for manufacturing the same | |
KR20110112263A (en) | Preparation method of skin rejuvenating agent using ingredients extracted from medicinal plants | |
KR101091002B1 (en) | Composition for improving condition of hair and scalp with function of preventing depilation and accelerating hair growth using natural extracts | |
CN103041042B (en) | Tibetan medicine composition and application of composition in anti-off hair products | |
KR100970126B1 (en) | Process for producing hair loss prevention and hair growth promoting composition | |
KR20190010814A (en) | Composition for hair growth | |
KR101598083B1 (en) | An antifungal composition comprising an natural fermentation material | |
KR101047612B1 (en) | Cosmetic composition for reducing or treating acne and acne rash | |
CN103877281A (en) | Pharmaceutical composition for treating chicken colibacillosis, and preparation method thereof | |
CN112294708A (en) | Weakly acidic hair washing and protecting active lotion | |
KR102167536B1 (en) | Cosmetic composition for anti-inflammation or improving skin trouble containing herb extracts | |
KR20140020513A (en) | Hair tonic composition having preventing alopecia and trichogenousness effect and manufacturing method thereof | |
CN107811902B (en) | Hair loss preventing and growing agent and preparation method thereof | |
KR102702964B1 (en) | Fermented low molecular collagen of using complex enzyme and its manufacturing method | |
KR101277359B1 (en) | Scalp and hair-care composition | |
KR102176983B1 (en) | Method of manufacturing cosmetic composition for acnes improvement and cosmetic composition for acnes improvement produced by the same | |
KR101723615B1 (en) | Shampoo Compositions Using Oriental Medicines | |
KR101188216B1 (en) | Natural complex extract Composition for preventing falling out of the hair and promoting growth of the hair containing black soybean paste's active principle | |
KR100885480B1 (en) | Herbal whitening composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20151021 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20161121 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20170629 Patent event code: PE09021S02D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20180131 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180419 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20180420 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20220414 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20230419 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20240423 Start annual number: 7 End annual number: 7 |